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Background: A hallmark of Alzheimer’s disease is the presence of senile plaques in human brain primarily
containing the amyloid peptides Aβ42 and Aβ40. Many drug discovery efforts have focused on decreasing the
production of Aβ42 through γ-secretase inhibition. However, identification of γ-secretase inhibitors has also
uncovered mechanism-based side effects. One approach to circumvent these side effects has been modulation of
γ-secretase to shift Aβ production to favor shorter, less amyloidogenic peptides than Aβ42, without affecting the
overall cleavage efficiency of the enzyme. This approach, frequently called γ-secretase modulation, appears more
promising and has lead to the development of new therapeutic candidates for disease modification in Alzheimer’s
disease.
Results: Here we describe EVP-0015962, a novel small molecule γ-secretase modulator. EVP-0015962 decreased
Aβ42 in H4 cells (IC50 = 67 nM) and increased the shorter Aβ38 by 1.7 fold at the IC50 for lowering of Aβ42. AβTotal,
as well as other carboxyl-terminal fragments of amyloid precursor protein, were not changed. EVP-0015962 did not
cause the accumulation of other γ-secretase substrates, such as the Notch and ephrin A4 receptors, whereas a
γ-secretase inhibitor reduced processing of both. A single oral dose of EVP-0015962 (30 mg/kg) decreased Aβ42 and
did not alter AβTotal peptide levels in a dose-dependent manner in Tg2576 mouse brain at an age when overt Aβ
deposition was not present. In Tg2576 mice, chronic treatment with EVP-0015962 (20 or 60 mg/kg/day in a food
formulation) reduced Aβ aggregates, amyloid plaques, inflammatory markers, and cognitive deficits.
Conclusions: EVP-0015962 is orally bioavailable, detected in brain, and a potent, selective γ-secretase modulator
in vitro and in vivo. Chronic treatment with EVP-0015962 was well tolerated in mice and lowered the production of
Aβ42, attenuated memory deficits, and reduced Aβ plaque formation and inflammation in Tg2576 transgenic
animals. In summary, these data suggest that γ-secretase modulation with EVP-0015962 represents a viable
therapeutic alternative for disease modification in Alzheimer’s disease.
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Alzheimer’s disease (AD) is a progressive neurodegen-
erative disease, first described in 1907 [1]. Functional
changes in this devastating disease include early memory
deficits and later deficits affecting language, executive
functioning, perception, and/or execution of complex
motor patterns [2]. The neuropathology in AD is charac-
terized by the presence of extracellular amyloid (Aβ) pla-
ques and intracellular neurofibrillary tangles in the
cerebral cortex, hippocampus, and amygdala, as well as
other brain regions associated with memory and other
domains of cognition [3]. The major constituents of the
amyloid plaques are well established and include the 4
kDa Aβ peptides, primarily Aβ42 and Aβ40 [4-7]. There
is considerable evidence suggesting that Aβ42 is depos-
ited early in the amyloid plaques and forms the seed for
later deposition of other Aβ species [5,8]. This evidence
has suggested that an early and constant reduction in
Aβ42 in prodromal AD might delay the onset or slow the
progression of the disease by affecting the rate of plaque
formation. Aβ42 is derived from sequential processing
of amyloid precursor protein (APP) by two proteases,
β-site APP-cleaving enzyme (BACE) and γ-secretase
[9,10]. Initially, BACE cleaves APP in its ectodomain,
followed by γ-secretase cleavage in the APP transmem-
brane domain [9,10], which ultimately produces a num-
ber of Aβ peptides of various lengths [11]. Significantly,
most familial AD mutations in the APP gene are found
around the BACE or γ-secretase cleavage sites, and thus
both BACE and γ-secretase have been targets for thera-
peutic intervention in AD [8,12].
γ-Secretase is a large complex composed of the four
polypeptides: presenilin (PS-1 or PS-2), nicastrin (Nct),
presenilin enhancer 2 (Pen-2), and anterior pharynx-
defective 1 (Aph-1) [7]. γ-Secretase is responsible for the
processing of more than 70 transmembrane proteins
involved in normal cellular processes, including regula-
tion of cell fate, cell adhesion, migration, neurite out-
growth, synaptogenesis, calcium homeostasis, transport
of membrane proteins, and cell signaling [13,14]. Muta-
tions in PS, the putative catalytic site of the γ-secretase
complex, and in APP around the γ-secretase cleavage site,
were shown to increase the ratio of Aβ42/Aβ40, strength-
ening support for γ-secretase inhibition for disease modifi-
cation in AD [8,12]. While inhibition of γ-secretase would
produce the desired Aβ reduction, it would also affect the
proteolysis of its other substrates. The Notch receptor is
one of these substrates [15], which is of particular interest
since the inhibition of its proteolytic processing by γ-
secretase inhibitors (GSIs) has been shown to result in the
suppression of intestinal goblet cell differentiation and in
immunosuppression [16]. Several GSIs have entered clin-
ical trials in AD, but unfortunately, have produced toxicities
that are presumably mechanism-based. In particular, onecompound (Semegacestat) produced drug-related rashes,
lightening of hair color, skin cancer, and more importantly,
worsening of cognition and the ability to perform activities
of daily living [17-19]. These mechanism-based toxicities of
GSIs have been attributed to the inhibition of Notch recep-
tor processing and to the accumulation of the APP β-
carboxyl-terminal fragment (CTF) [16,19].
Neuroinflammation is another pathological hallmark of
AD and is characterized by the presence of activated
microglia and reactive astrocytes surrounding the amyloid
plaques [20]. The question of whether the gliosis is causa-
tive or a compensatory result of the amyloid plaque depo-
sition has been the subject of ongoing discussions and
studies since it was first described [20,21]. For example,
numerous retrospective studies associated a lower inci-
dence of AD in patient populations that were prescribed
non-steroidal anti-inflammatory drugs (NSAIDs) for other
conditions [20]. It was therefore assumed that the NSAID
therapy exerted positive effects on AD by reducing neuro-
toxic inflammation through the reduction of cyclooxygen-
ase (COX) activities [20]. However, Weggen et al. [22,23]
described a series of in vitro and in vivo studies utilizing
several NSAIDs that produced a preferential reduction
of Aβ42 compared to Aβ40. This reduction of Aβ42 was
accompanied by a concomitant increase in Aβ38, a shorter,
less amyloidogenic Aβ peptide [12], rather than the inhib-
ition of all carboxyl-terminal processing of APP [22,23].
Furthermore, they demonstrated that the effects of
NSAIDs on the preferential reduction of Aβ42 peptide
levels were not linked to the inhibition of COX or other
enzymes, but rather to a specific action on γ-secretase
[22,24]. The shift in production of Aβ peptides from the
longer, toxic forms to the shorter, less toxic forms by
NSAIDs has been termed γ-secretase modulation. This
has sparked a flurry of activity directed at the development
of compounds that modulate APP cleavage by γ-secretase
and that could avoid the toxicities arising from the
complete enzymatic inhibition of γ-secretase. Several re-
cent publications have described second generation γ-
secretase modulators (GSMs) [25-29] and Notch-sparing
GSIs [18,30]. Here we present the in vitro and in vivo
characterization of EVP-0015962, a potent, second gene-
ration GSM that specifically modulated production of
Aβ42 and Aβ38 without affecting other γ-secretase sub-
strates. In transgenic mice over-expressing APP, EVP-
0015962 was well tolerated following chronic dosing,
produced reductions in amyloid plaque burden and neu-
roinflammation, and improved cognition.
Results
EVP-0015962 selectively reduces the levels of Aβ42
in vitro
In the course of a traditional drug discovery effort aimed
at identifying novel compounds with GSM activity, EVP-
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fluoromethyl)biphenyl-3-yl)-3-cyclobutylpropanoic acid,
was identified and characterized (Figure 1). Using
human neuroglioma H4 cells, stably transfected with
human wild type APP751 (H4-APP751 cells), EVP-
0015962 demonstrated a dose-dependent decrease in the
levels of Aβ42 after overnight incubation, while the levels
of AβTotal remained unchanged up to 3 μM (Figure 2A).
The mean IC50 for Aβ42 was 67 ± 5 nM (n = 6). No ef-
fect was observed on AβTotal until the concentration of
EVP-0015962 reached levels at which cytotoxicity was
observed in the MTS assay (IC50 = 5.56 ± 0.51 μM, n =
6). The mean EC50 for Aβ38 was 33 ± 4 nM (n = 6). At
the IC50 for Aβ42, the mean fold increase in Aβ38 was
1.7. The patterns of the Aβ isoforms were also analyzed by
matrix-assisted laser desorption/ionization-time-of-flight
(MALDI-TOF) mass spectrometry after treatment of H4-
APP751 cells with DMSO or 700 nM (IC90) of EVP-0015962
(Figure 3A-B). The relative quantification of selected Aβ iso-
form peak heights for EVP-0015962 treatment compared
with DMSO treatment showed that EVP-0015962 decreased
Aβ42 and Aβ39 production, increased Aβ38 and Aβ33 pro-
duction, and did not change Aβ40 and Aβ37 production.
The potency of EVP-0015962 was also evaluated in rat
primary neocortical cultures. In these studies, EVP-
0015962 lowered the levels of Aβ42 with an average IC50
of 427 ± 52 nM (n = 4), while the IC50 values for the
levels of Aβ1-x peptides and cytotoxicity were > 30 μM
(n = 4) (Figure 2B). The mean EC50 for Aβ38 was 384 ±
11 nM (n = 2). At the IC50 for Aβ42, the mean fold in-
crease in Aβ38 was 3.0. These results suggest that EVP-
0015962 acts as a typical GSM.Figure 1 The chemical structure of EVP-0015962.EVP-0015962 does not impair other γ-secretase cleavages
Most, if not all, γ-secretase substrates undergo ectodomain
shedding; and the resulting CTFs are released from the
membrane by γ-secretase [14]. This cleavage also leads to
the production of intracellular domains (ICDs) of the γ-
secretase substrates [14]. Inhibition or loss of γ-secretase
has been shown to prevent the formation of these ICDs,
and consequently to lead to the accumulation of CTFs of
the γ-secretase substrates [15,19,29-33]. In the case of APP,
the products of α- and β-secretase cleavages (α- and β-
CTFs, respectively) are cleaved by γ-secretase to produce
the APP intracellular domain (AICD). As shown in
Figure 4A, in a cell-free system using reconstituted γ-
secretase, up to 100 μM of EVP-0015962 did not pre-
vent the production of AICD from APP β-CTF, whereas
treatment with the GSI, N-(N-(3,5-difluorophenacetyl)-
L-alanyl)-S-phenylglycine t-butyl ester (DAPT), almost
completely abolished AICD production at 10 μM. In
this cell-free assay, EVP-0015962 selectively reduced
Aβ42 levels with an IC50 of 3.9 μM, without affecting the
levels of Aβ40 (Figure 2C-D). Recently, accumulation
of APP β-CTF after chronic treatment with GSIs has
been implicated in cognitive impairment [19]. We also
showed that EVP-0015962 treatment of H4-APP751 cells
did not cause the accumulation of APP α- or β-CTFs at
concentrations up to 10 μM, whereas the GSI LY-411,575
[16] led to their accumulation at a concentration as low as
1 nM (Figure 4B). Full length APP was not altered by
treatment with either EVP-0015962 or LY-411,575, con-
sistent with published findings [27,30,33,34].
The inhibition of Notch intracellular domain (NICD)
production is a well-characterized consequence of γ-
secretase inhibition and has been linked to many of the
toxicities associated with GSIs [16-18,31]. In HEK293 cells
expressing NotchΔE, EVP-0015962 did not affect levels of
NICD produced or cell viability at concentrations up to 30
μM (Figure 4C-D). Finally, inhibition of the processing of
one member of the ephrin (Eph) receptor family (EphA4)
by GSIs was reported to inhibit dendritic spine formation
in primary neurons [35]. The effects of EVP-0015962 and
LY-411,175 on EphA4 CTF accumulation in rat primary
neocortical cultures were assessed. Up to 10 μM of EVP-
0015962 did not result in EphA4 CTF accumulation,
whereas a concentration as low as 100 nM of LY-411,175
led to EphA4 CTF accumulation (Figure 4E-F).
Single doses of EVP-0015962 reduce Aβ42 in Tg2576 mice
Acute dosing of EVP-0015962 was studied in male Tg2576
mice at 21 weeks, an age before the onset of Aβ deposition
in this transgenic APP over-expression model [36]. Four
hours after administration of EVP-0015962 at 10 or 30 mg/
kg, p.o., Aβ peptides were extracted from brain using Tris
buffered saline (TBS). Overall, Aβ42 was significantly
decreased by EVP-0015962 (F[2,9] = 4.74, p = 0.039,
Figure 2 EVP-0015962 is a potent γ-secretase modulator. A. Concentration response curves for Aβ42, Aβ38, and AβTotal determined by
enzyme-linked immunosorbent assay (ELISA), and for cell viability in the H4-APP751 cell assay. IC50 = 67 nM for Aβ42 and EC50 = 33 nM for Aβ38.
For cell viability determined using the MTS assay, IC50 = 5.56 μM. IC50 > 3 μM for AβTotal. For Aβ38, the EC50 value is determined for the
concentration range of 3 nM to 1 μM of EVP-0015962, to avoid the portion of the curve where toxicity is observed. N = 6 independent
experiments. B. Concentration response curves for Aβ42, Aβ38, and Aβ1-x determined by ELISA in media and for MTS from rat primary neocortical
cultures. IC50 = 427 nM for Aβ42 and EC50 = 384 nM for Aβ38. IC50 > 30 μM for Aβ1-x and the MTS assay. N = 4 independent experiments for Aβ42,
Aβ1-x, and MTS and 2 for Aβ38. C. Concentration response curve for Aβ42 in the cell-free assay. IC50 = 3.9 μM. D. Concentration response curve for
Aβ40 in the cell-free assay. In the cell-free assays, Aβ was determined by AlphaLisa in triplicate. All data are expressed as mean ± standard error of
the mean (SEM). For some data points, error bars are smaller than the sizes of the data points.
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were 22% for 10 mg/kg (NS) and 39% for 30 mg/kg of
EVP-0015962 (p < 0.05). AβTotal remained unchanged by
EVP-0015962 treatment (F[2,9] = 0.085, p = NS,
Figure 5B).
Chronic administration of EVP-0015962 is well tolerated
and decreases brain Aβ levels in Tg2576 mice
The goal of the chronic study was to determine the effects
of EVP-0015962 on AD-like pathology in Tg2576 mice
when daily treatment was begun at 17–26 weeks of age,
before visible Aβ deposition is detected in this mouse
model [36]. EVP-0015962 was administered to Tg2576
mice for 50 weeks in a food formulation. The concentra-
tions of EVP-0015962 used in the food formulations were
determined in pilot studies. Based on the minimum effect-
ive brain exposures to produce Aβ reductions after single
doses of 10 and 30 mg/kg, p.o. in Tg2576 mice (1.3 and
4.3 μM, respectively at 4 h post-dosing), the compoundconcentrations of 20 and 60 mg/kg/day in the food formu-
lations were selected. In C57BL/6 mice fed with the food
formulations of 20 and 60 mg/kg/day for 3 or 7 days,
the ranges of brain concentrations were 1.5–3.1 and 4.9–
9.7 μM, respectively (n = 3 studies). After 50 weeks, brain
concentrations of EVP-0015962 in the chronically treated
Tg2576 mice were 2.5 ± 0.2 and 8.3 ± 0.6 μM for 20 and
60 mg/kg/day, respectively. Thus, the brain concentrations
of EVP-0015962 were within the expected range observed
after short-term treatments and did not demonstrate accu-
mulation or cytochrome P450 enzyme induction.
Body weights were tracked throughout the study to as-
sess the long term tolerability of EVP-0015962 (Figure 6).
All mice gained a significant amount of weight during
the course of treatment (p < 0.001), and there were no
significant differences in body weight among the treat-
ment groups at any time point during the study. These
data indicated that chronic EVP-0015962 treatment was
well tolerated.
Figure 3 EVP-0015962 selectively affects processing of Aβ isoforms. A and B. Effect of EVP-0015962 treatment on production of Aβ
isoforms, measured by MALDI-TOF mass spectrometry. Mass spectra from H4-APP751 cells treated with DMSO (A) and 700 nM EVP-0015962
(B). It should be noted that a relative quantification cannot be interpreted as a direct reflection of an absolute or relative abundance of a species
since the ionization efficiency and hydrophobicity might be different for different Aβ isoforms. N = 1 experiment.
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sequentially extracted Aβ using TBS, TritonW-X, sodium
dodecyl sulfate (SDS), and formic acid [37] were also
evaluated. The results of the TritonW-X fraction resembled
those of the TBS fraction, and the results of the SDS frac-
tion resembled those of the formic acid fraction. Therefore
only the TBS (Figure 7A, C, E) and formic acid (Figure 7B,
D, F) fractions are described. Aβ42 was significantly low-
ered in both the TBS soluble and formic acid extractable
fractions (TBS, F[2,12] = 12.3, p = 0.001; formic acid,
F[2,12] = 27.2, p < 0.001; Figure 7A-B). The percent reduc-
tion in Aβ42 in the TBS soluble fraction was 53% for
20 mg/kg/day (p < 0.05) and 89% for 60 mg/kg/day
(p < 0.001). Similarly, formic acid extractable Aβ42 was
reduced for the 20 and 60 mg/kg/day doses by 53% and
86%, respectively (p < 0.001). In contrast, Aβ38 in the TBS
soluble fraction was increased by treatment with EVP-
0015962 (F[2,12] = 5.37, p = 0.022, Figure 7C). Treatment
with 60 mg/kg/day of EVP-0015962 increased Aβ38 by 78%
(p < 0.05), but 20 mg/kg/day did not produce a significant
increase. In the formic acid extractable fraction, Aβ38 was
not significantly changed, despite a trend (p = 0.055 by
t-test) towards a decrease in the 60 mg/kg/day group
(Figure 7D). AβTotal was unchanged in the TBS solublefraction (Figure 7E), but was reduced in the formic acid ex-
tractable fraction (F[2,12] = 8.59, p = 0.005, Figure 7F). The
reductions were 49% (p < 0.05) and 64% (p < 0.01) at 20
and 60 mg/kg/day of EVP-0015962, respectively. During
the chronic study, Aβ peptide levels were evaluated after 11
and 28 weeks of dosing in additional Tg2576 mice. Aβ42
peptide levels from the TBS soluble and insoluble fractions
increased exponentially in mice on the control diet
(Figure 7G-H). Treatment with 60 mg/kg/day of EVP-
0015962 for 50 weeks prevented the dramatic increase in
both soluble and insoluble Aβ42 that is normally associated
with Aβ deposition in this mouse model. The lower dose of
EVP-0015962 was partially effective in preventing the in-
crease in Aβ42 over the course of the 50-week treatment.
Aggregated Aβ, measured by the Amorfix aggregated
Aβ assay, was detectable in all groups of Tg2576 mice
and was reduced by 50 weeks of treatment with EVP-
0015962 (H[3] = 10.28, p = 0.006, Figure 8A). There was
a significant reduction in aggregated Aβ of 73% in the
group receiving 60 mg/kg/day of EVP-0015962 com-
pared to the control diet group (p < 0.01).
Brain samples were also analyzed by Western blotting to
determine whether 50 weeks of treatment with EVP-
0015962 resulted in accumulation of APP CTFs. There
Figure 4 EVP-0015962 does not alter processing of APP or
other γ-secretase substrates. A. Effect of EVP-0015962 treatment
on the ε-cleavage of APP β-CTF, measured in a cell-free assay with
Aph1AL containing γ-secretase complexes. Representative Western
blot of AICD fragments, for EVP-0015962 (1 nM to 100 μM) and
DAPT (10 μM). DMSO is the control lane. N = 2 experiments. B. Full
length APP (flAPP), α-CTF, and β-CTF from H4-APP751 cell lysates,
analyzed by Western blot after a 16-h treatment with 1 nM to 10 μM
of LY-411,575 or EVP-0015962. N = 1 experiment. C and D. Effect of
EVP-0015962 treatment (1 nM to 30 μM) on the S3 cleavage of
NotchΔE to form NICD, measured in transfected HEK293 cells.
C. Representative Western blot of NICD fragments fluorescently
labeled with cleaved Notch1 antibody (green) and Myc-tagged
antibody (red). The NICD fragments are detected as yellow in an
overlay of both antibodies. DMSO is the control lane and Empty
vector is a lysate from cells without the NotchΔE construct. D. NICD
intensity histogram corresponding to the Western blot in E. NICD is
quantified as a percentage of total Notch. N = 2 experiments. E and
F. Effect of 24 h of treatment with 100 nM to 10 μM of LY-411,575
or EVP-0015962 on the production of EphA4 CTF in cell lysates from
rat primary neocortical cultures. E. Western blot of full length (FL)
EphA4 (upper band) and EphA4 CTF (lower band). F. Ratio of EphA4
CTF to full length EphA4 corresponding to the Western blot in
E. N = 1 experiment.
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and α-CTF (Figure 8B-C) for mice at either dose com-
pared to mice on control diet. On the other hand, total Aβ
was significantly and dose dependently decreased by EVP-
0015962 treatment (F[2,7] = 27.5, p < 0.001, Figure 8B, D).
Compared to Tg2576 mice on the control diet, the reduc-
tions were 42% (p < 0.01) and 81% (p < 0.001) for the
20 and 60 mg/kg/day groups, respectively. This sugges-
ted that while long-term treatment with EVP-0015962
decreased Aβ levels, it did not inhibit the overall proces-
sing of APP CTFs by γ-secretase in vivo.
Chronic treatment with EVP-0015962 inhibits plaque
formation and inflammation
Histological evaluation of amyloid plaques was performed
with ThioflavinS fluorescence to visualize compact cores
specifically and with 6E10 antibody immunostaining for
the compact cores and the surrounding halo of more dif-
fuse Aβ (Table 1, Figure 9A-B). Tg2576 mice treated for
50 weeks with EVP-0015962 showed a significant reduc-
tion in percent area and number of amyloid plaques in the
hippocampus by immunostaining with 6E10 antibody
(percent area, F[2,18] = 4.13, p = 0.033; number, F[2,18] =
4.79, p = 0.022). There was no effect on the mean plaque
size. These reductions were seen for both the 20 and 60
mg/kg/day groups (p < 0.05). In the neocortex, the reduc-
tions in percent area and number of 6E10-positive amyloid
plaques were trends (percent area, F[2,18] = 2.60, p =
0.102; number, F[2,18] = 3.51, p = 0.052). In addition,
EVP-0015962 significantly reduced the percent area and
number of ThioflavinS-positive amyloid plaque cores in
the hippocampus (percent area, F[2,18] = 8.13, p = 0.003;
Figure 5 In Tg2576 mice, a single dose of EVP-0015962
decreases brain Aβ42 without altering AβTotal. Brain
concentrations of Aβ42 (A) and AβTotal (B), measured 4 h after 10 or
30 mg/kg, p.o. of EVP-0015962 by sandwich ELISAs, following TBS
extraction. Graphs illustrate mean + SEM, N = 4 per group.
Difference from the vehicle-treated group: *p < 0.05 (1-way ANOVA,
post-hoc Newman-Keuls test).
Figure 6 Chronic daily exposure to EVP-0015962 in Tg2576
mice is well tolerated. Body weight change in Tg2576 mice,
measured weekly beginning the week prior to chronic dosing with
EVP-0015962 in a food formulation at 20 or 60 mg/kg/day and
continuing through the course of treatment. There are no group
differences in body weight change (2-way repeated measures
ANOVA, within subjects variable – week and between subjects
variable – drug treatment). Data are the mean ± SEM of 6–8 mice
per group. Arrow indicates the start of treatment with EVP-0015962.
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the hippocampus reached significance for both the 20
and 60 mg/kg/day groups for percent area (p < 0.01)
and number (p < 0.05) of plaque cores. In the neocortex,
the percent area and number of ThioflavinS-positive
plaque cores were also significantly reduced (percent
area, F[2,18] = 5.20, p = 0.017; number, F[2,18] = 3.57,
p = 0.049). At the high dose, percent area of plaque
cores was significantly reduced in the neocortex (p <
0.05), while plaque number trended lower (t-test, p =
0.054). The size of ThioflavinS-positive plaque cores
trended lower in the neocortex and hippocampus after
EVP-0015962 treatment (neocortex, F[2,18] = 3.53, p =
0.051; hippocampus, F[2,18] = 2.50, p = 0.110). In the
neocortex, the post hoc test for plaque core size was
nevertheless significant for the comparison of the control
diet group with the group treated with 60 mg/kg/day of
EVP-0015962 (p < 0.05).Concurrent with the reduction in amyloid pathology,
reactive astrocytosis, visualized by immunostaining with
an antibody against glial fibrillary acidic protein (GFAP),
trended lower in the neocortex (F[2,18] = 2.72, p = 0.093;
Table 1, Figure 9C-D). By t-test, the 60 mg/kg/day group
was significantly lower than the control diet group
for percent area of reactive astrocytes in the neocortex
(p = 0.038). Activated microglia, immunostained with
an antibody against CD11b, trended lower in both the
neocortex and hippocampus (neocortex, F[2,18] = 2.57,
p = 0.104; hippocampus, F[2,18] = 3.37, p = 0.057; Table 1,
Figure 9C-D). By t-test, the reduction in activated micro-
glia reached significance in a comparison of 60 mg/kg/day
and control diet groups in the hippocampus (p = 0.046),
but was a trend in the neocortex (p = 0.069).
Contextual fear conditioning deficits are reversed by
chronic treatment with EVP-0015962
Contextual fear conditioning (CFC) is an important behav-
ioral assay for studying learning and memory related to
hippocampal function [38], and has shown deficits in
Tg2576 mice that are reversed by both GSIs and GSMs
[39,40]. Beginning at 19–22 weeks of age, Tg2576 mice
were treated with EVP-0015962 and Tg2576 and WT mice
were treated with control diet for 11 weeks. In the CFC
assay there was an overall significant effect on percent
freezing behavior (F[3,46] = 5.95, p = 0.002, Figure 10A).
In post hoc analysis, a cognitive deficit (decrease in percent
freezing behavior) was detected at 30–33 weeks of age in
the Tg2576 mice on control diet compared to WT mice
on control diet (p < 0.01). This genotype-associated deficit
in theTg2576 mice was reversed by treatment with 20 or
60 mg/kg/day of EVP-0015962 (p < 0.01).
Figure 7 Chronic daily exposure to EVP-0015962 in Tg2576 mice reduces Aβ peptide levels. A-F. TBS soluble (A, C, E) and formic acid
extractable (B, D, F) Aβ peptide levels determined by ELISA from the brains of Tg2576 mice after 50 weeks of treatment with EVP-0015962 for
Aβ42 (A-B), Aβ38 (C-D), and AβTotal (E-F). N = 5 mice per group. Differences from the control diet group: *p < 0.05, **p < 0.01, ***p < 0.001
(1-way ANOVA, post-hoc Newman-Keuls test). G-H. Aβ42 peptide levels measured at the beginning of treatment and after 11, 28, and 50 weeks of
treatment with EVP-0015962, showing the time course of accumulation of Aβ42. G. TBS soluble Aβ42. H. Insoluble Aβ42. At 11 and 28 weeks,
insoluble Aβ42 was extracted with only formic acid. At 0 and 50 weeks, the 4-step procedure was used, and the insoluble fraction is the sum of
the Aβ42 extracted with TritonW-X, SDS, and formic acid. N = 4–6 mice per group and time point. Graphs illustrate mean ± SEM.
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Figure 8 Chronic daily exposure to EVP-0015962 in Tg2576 mice reduces Aβ without affecting APP α- and β-CTFs. A. Aggregated Aβ,
measured by the A4 assay and expressed as a percent of the control diet group in 17-month-old mice. N = 9–10 mice per group. Difference from the
control diet group: **p < 0.01 (Kruskal-Wallis ANOVA, post-hoc Dunn’s test). B. Representative Western blot for the different peptide species of APP for
Tg2576 mice on the control diet and treated with 20 or 60 mg/kg/day of EVP-0015962. C. Quantification of relative optical density (ROD) from Western
blots for full length APP (flAPP), β-CTF, and α-CTF. D. Quantification of ROD from Western blots for Total Aβ. N = 3–4 mice per group. Graphs illustrate
mean + SEM. Differences from the control diet group: **p < 0.01, ***p < 0.001 (1-way ANOVA, post-hoc Newman-Keuls test).
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age received a single administration of EVP-0015962 (30
mg/kg, p.o.) on day 1, 3 h prior to the training session, in
order to evaluate whether there were any acute effects of
EVP-0015962 treatment on cognition. Overall, there were
group differences in percent freezing (F[3,48] = 5.67, p =
0.002, Figure 10B). There was a significant genotype-
associated deficit in the Tg2576 mice compared with WT
mice for the vehicle-treated mice and EVP-0015962-
treated mice (t-tests, p < 0.05). However, neither the
Tg2576 nor WT mice treated with 30 mg/kg, p.o. of EVP-
0015962 showed an increase in percent freezing compared
to their respective vehicle-treated groups.
Discussion
The presence of neuroinflammation in AD and the seem-
ingly positive effects of chronic NSAID usage on the reduc-
tion of the risk of developing AD in retrospective
epidemiological studies [20,41] suggested that NSAIDsmight be operating via the inhibition of COX or activation
of the peroxisome proliferator-activated receptor γ. Indeed,
studies in Tg2576 mice generated evidence to support this
hypothesis. Tg2576 mice that were fed a diet of 375 ppm of
ibuprofen for 4–6 months, showed a marked decrease in
amyloid plaque load, as well as in inflammatory mediators,
such as interleukin-1β, GFAP, and markers of microglial ac-
tivation [42,43]. However, subsequent mechanistic studies
suggested that certain NSAIDs were able to produce a pre-
ferential reduction of Aβ42, without altering the levels of
other Aβ peptides, presumably through a direct modulation
of γ-secretase [22,23,44]. The result of γ-secretase modula-
tion by NSAIDs was an overall shift in the Aβ42/Aβ40 ratio,
with an accompanying increase in the shorter Aβ38, both of
which were not correlated to COX activity or the activity of
other enzymes inhibited by NSAIDs [22-24].
The first generation GSM to be tested in the clinic
was Flurizan™, the R enantiomer of the racemate
NSAID, flurbiprofen [44,45]. Flurizan™ has the classic
Table 1 Mean (± sem) percent of control after chronic of treatment with EVP-0015962 at 20 or 60 mg/kg/day
Neocortex Hippocampus
Stain and pathology Control EVP-0015962 (mg/kg/day) Control EVP-0015962 (mg/kg/day)
Parameter diet 20 60 diet 20 60
6E10 immunostaining of Aβ plaque pathology
Percent area 100 (10.8) 69.2 (9.7) 65.3 (16.3) 100 (10.8) 62.1 (13.2)* 53.1 (15.2)*
Number/mm2 100 (7.9) 65.2 (8.8) 71.3 (15.0) 100 (9.7) 61.0 (12.2)* 53.9 (16.8)*
Size (μm2) 100 (6.5) 105.5 (8.8) 88.5 (5.4) 100 (16.4) 99.4 (15.7) 104.1 (11.6)
ThioflavinS staining of Aβ plaque pathology
Percent area 100 (18.0) 64.3 (14.3) 29.9 (7.3)* 100 (14.7) 40.7 (16.9)** 27.3 (6.5)**
Number/mm2 100 (12.4) 64.3 (8.0) 59.6 (14.1) 100 (12.7) 55.2 (15.6)* 50.7 (12.8)*
Size (μm2) 100 (8.5) 87.8 (12.2) 58.1 (10.6)* 100 (6.8) 56.5 (16.3) 58.9 (27.0)
GFAP immunostaining of reactive astrocytes
Percent area 100 (12.5) 95.8 (14.5) 61.6 (7.6) 100 (9.0) 95.8 (7.7) 87.2 (9.7)
CD11b immunostaining of activated microglia
Percent area 100 (12.8) 86.3 (5.0) 66.2 (7.7) 100 (12.1) 69.8 (9.2) 61.8 (10.7)
*p<0.05, **p<0.01 compared with Tg2576 mice on control diet by 1-way ANOVAs and post-hoc Newman-Keuls tests.
N = 9 mice in the control diet group and 6 in the EVP-0015962 treatment groups.
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http://www.molecularneurodegeneration.com/content/7/1/61GSM signature of lowering Aβ42 without affecting the
total amount of Aβ peptides. However, Flurizan™ was a
relatively weak GSM (IC50 > 300 μM for Aβ42 [46]), with
low brain concentrations in animals and man, and was
subsequently withdrawn from clinical evaluation due to
the lack of efficacy in a large phase III trial [47]. More
recently, second generation GSMs from multiple chem-
ical classes have been reported, which have improved
potency and brain concentrations [25-29,44,48]. In the
current study, we have characterized EVP-0015962, a
potent small molecule compound, which has a substan-
tially improved potency (4,500-fold) and pharmaco-
logical profile compared with Flurizan™. EVP-0015962
had a measured LogD of 3.88 and was present in the
brain at 1.3 to 4.3 μM after single oral doses of 10 and
30 mg/kg, respectively. Moreover, we have demonstrated
that γ-secretase activity is modulated by EVP-0015962
to selectively decrease Aβ42 levels (IC50 = 67 nM) in
H4-APP751 cells, and increase levels of the shorter Aβ38
peptide (EC50 = 33 nM), without a change in AβTotal
(composed primarily of Aβ40 [7]) or in Aβ peptides of
other lengths. These changes in the levels of Aβ42 and
Aβ38 peptides were seen in the in vitro assay systems, as
well as in vivo in Tg2576 mice after acute treatment.
The lack of overall change in Aβ peptide levels and the
increase in Aβ38 by EVP-0015962 suggest selective
modulation, rather than inhibition of the γ-secretase en-
zyme complex, similar to the mechanism of action of
other GSMs with similar chemotypes [48]. In contrast,
GSMs of other chemical classes do reduce Aβ40 peptide
levels, albeit with a higher IC50 than that for Aβ42, sug-
gesting that they might function differently than EVP-
0015962 [29,48].We further substantiated the modulatory effects of
EVP-0015962 by determining whether the compound
inhibited the S3/ε-cleavage activity of the γ-secretase
complex at its other natural substrates. EVP-0015962
did not inhibit the ability of γ-secretase to generate
AICD and NICD in vitro. As expected from a lack of
effect on AICD formation, no accumulation of APP
α- and β-CTFs was observed in the presence of EVP-
0015962 either in vitro or in vivo. EVP-0015962 also did
not cause the accumulation of EphA4 CTF. The lack of
effect on the processing of other γ-secretase substrates is
thus also consistent with γ-secretase modulation. This
suggests that EVP-0015962 may avoid the mechanism-
based side effects that have been previously associated
with GSIs (e.g., intestinal goblet cell hyperplasia and im-
munosuppression due to inhibition of Notch receptor
processing and cognitive impairment due to the accu-
mulation of APP β-CTF) [16,19]. Furthermore, in our
longitudinal efficacy study in Tg2576 mice, in which we
observed a significant reduction of Aβ42, we found no
evidence of effects on intestinal goblet cells or on any
other organ system examined in satellite animals treated
with up to 60 mg/kg/day of EVP-0015962 for 11 weeks.
The tolerability of EVP-0015962 was also demonstrated
by the similar weight gains at the 20 and 60 mg/kg/day
doses of EVP-0015962, when compared to Tg2576 mice
on the control diet for 50 weeks. In addition, when sur-
vival was examined after 50 weeks of treatment, 25% of
the high (60 mg/kg/day) dose group was lost compared
to 27% of the control diet group. The observed mortality
rates were consistent with the > 20% rates reported for
this transgenic model by the supplier (http://www.taconic.
com/wmspage.cfm?parm1=2646).
Figure 9 Chronic daily exposure to EVP-0015962 in Tg2576 mice reduces Aβ deposition and reactive gliosis. Representative sections
illustrating staining of amyloid plaques with ThioflavinS (green) and by immunohistochemistry (6E10, red) in the subiculum of the hippocampus
from Tg2576 mice fed either a control diet (A) or treated with 20 mg/kg/day of EVP-0015962 (B). Representative sections illustrating
immunohistochemical staining of reactive astrocytes (GFAP, green) and activated microglia (CD11b, red) in the subiculum from Tg2576 mice, fed
either a control diet (C) or treated with 60 mg/kg/day of EVP-0015962 (D). Nuclei are stained with 4',6-diamidino-2-phenylindole (DAPI, blue).
In C, amyloid deposits are visualized by the presence of interspersed fine microglial processes and are surrounded by activated microglia and in
turn by GFAP-positive astrocytes.
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to determine the effects of EVP-0015962 on AD-like
pathology in a transgenic mouse model. The Tg2576
mouse model expresses high levels of APP and Aβ with
a transgene containing human APP695 bearing the
Swedish mutation (K670N/M671L) behind the hamster
prion protein gene promoter [36]. One significant ad-
vantage of the Tg2576 model is that diffuse and neuritic
plaques begin to appear at approximately 6–7 months
and, along with extractable Aβ, increase with age [37].
Furthermore, these age-related changes are coincident
with the appearance of cognitive deficits [36,49], sug-
gesting that these mice are a useful tool for studies of
Aβ modifying therapies.
In an interim assessment, after 11 weeks of chronic
treatment with EVP-0015962, we examined the behavioral
effects of GSM treatment. Studies have shown that treat-
ments that lower Aβ can restore cognitive function in
these animals [39,40]. In the CFC assay, which is primarily
hippocampal dependent [38], the Tg2576 mice displayed
the expected cognitive deficit in contextual memory at
30–33 weeks of age. Importantly, the cognitive deficit was
reversed and/or prevented at both dose levels following 11
weeks of treatment with EVP-0015962. Separate groups of
Tg2576 and WT mice received a single administrationof EVP-0015962 (30 mg/kg, p.o. on day 1, 3 h prior to
training) in order to evaluate the acute effects of EVP-
0015962 treatment on CFC. Overall, differences between
the genotypes were observed in this study (i.e., a genotype-
associated deficit in the Tg2576 mice). However, acute
dosing with EVP-0015962 did not reverse this deficit. This
is in contrast to the report that 100 mg/kg, p.o. of the GSI
DAPT, administered 3 h before training in Tg2576 mice,
lowered Aβ levels and rapidly improved the CFC cognitive
deficit [39]. The WT mice, however, did not have improved
CFC performance after DAPT treatment, suggesting that
the effect was due to Aβ lowering, rather than to a general
cognitive enhancing effect, as observed with rolipram in
the same study. It is unclear by what mechanism a GSI
improved cognition acutely and why the GSM EVP-
0015962 did not. In a Y-maze spontaneous alternation test
of 5.5-month-old Tg2576 mice, acute GSI treatments also
improved short term spatial memory, but 8 days of treat-
ment did not [19]. This lack of effect of subchronic treat-
ment with GSIs on spatial memory was attributed to the
accumulation of APP β-CTF in hippocampal synapses and
was consistent with findings in the clinic of worsening of
cognition and the ability to perform activities of daily living
in AD patients [18]. In contrast, GSM-2 improved short
term spatial memory after both 1 and 8 days of treatment,
Figure 10 Chronic daily exposure to EVP-0015962 in Tg2576
mice reverses a cognitive decline. A. Percent freezing in the CFC
behavioral assay after chronic treatment with EVP-0015962 for 11
weeks in wild type (WT) and Tg2576 (Tg) mice, aged 30–33 weeks.
Difference between WT and Tg2576 mice on control diet
(i.e., genotype effect): ++p < 0.01. Differences from Tg2576 mice on
control diet (i.e., treatment effect): **p < 0.01. N = 10–15 mice per
group. B. Percent freezing comparing WT and Tg2576 at 30 weeks
of age and treated with a single acute dose of 30 mg/kg, p.o. of
EVP-0015962 or vehicle. Differences from WT mice receiving the
same treatment, either vehicle or 30 mg/kg of EVP-0015962:
+p < 0.05, indicating a genotype effect but no treatment effect.
N = 10–15 mice per group. All statistical analyses were performed
with 1-way ANOVAs and post-hoc Newman-Keuls tests or t-tests.
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observed under some experimental conditions [19].
After 50 weeks of chronic daily treatment with EVP-
0015962 in a food formulation, which began before
amyloid plaque deposition (17–26 weeks of age), brain
levels of soluble Aβ42 were dose dependently reduced.
Additionally, increased levels of Aβ38 were observed in
the TBS soluble pool of Aβ in the 60 mg/kg/day group.
AβTotal was not changed, similar to what was observedin C57BL/6 mice (data not shown) and Tg2576 mice
administered a single dose of EVP-0015962. These find-
ings indicated that EVP-0015962 was modulating Aβ
production in the Tg2576 mice in a similar fashion,
whether there were Aβ deposits or not. In addition, Aβ
peptides, particularly Aβ42 and AβTotal (primarily Aβ40),
were decreased in the formic acid extractable pool, albeit
to different extents. Since Aβ deposits contain all lengths
of Aβ peptides but are primarily composed of Aβ42 and
Aβ40 [4-7], this finding is consistent with a reduction in
Aβ deposition and is supportive of a potential disease
modifying effect of EVP-0015962.
As suggested by the reductions in insoluble Aβ peptide
levels after chronic treatment with EVP-0015962, Aβ aggre-
gates were also significantly lowered by the high-dose treat-
ment. The degree of reduction in aggregated Aβ (73%) after
treatment with 60 mg/kg/day of EVP-0015962 was consist-
ent with the reduced levels of Aβ42 detected by enzyme-
linked immunosorbent assay (ELISA) after formic acid ex-
traction of insoluble Aβ (86%) and of Total Aβ detected by
Western blotting (81%). Interestingly, more disparity among
the measures in amount of Aβ reduction was observed for
the 20 mg/kg/day treatment. In the aggregated Aβ assay the
reduction was 19%, whereas the reductions by ELISA and
Western blotting were larger and similar (about 40–50%).
Chronic treatment of Tg2576 mice with other GSMs
has demonstrated reductions in amyloid deposition [25-
27]. Similarly, the histological analyses of the chronically
treated Tg2576 mice demonstrated reductions in percent
area and number of amyloid plaques in the neocortex
and hippocampus. Although there was only a small non-
significant difference between the two doses of EVP-
0015962, there was a general trend towards a more pro-
nounced effect at the 60 mg/kg/day dose. Significant
reductions were observed in the aggregated Aβ of the
plaque cores (visualized with ThioflavinS) and in the
more diffuse Aβ surrounding the plaque cores (visua-
lized with the 6E10 antibody) [50-53]. Although both
staining procedures produced significant EVP-0015962
treatment effects for percent area and number of pla-
ques, plaque size was only reduced in the ThioflavinS
analysis. Since the cores of amyloid plaques are initially
seeded by aggregated Aβ42 [5], and this is the peptide
most reduced by EVP-0015962 treatment, it is likely that
the higher number of significant findings with Thiofla-
vinS relates to its preferential staining of the plaque
cores, while 6E10 antibody recognizes Aβ of various
lengths and states of aggregation, which were less altered
overall by the treatment. This suggests that EVP-
0015962 might mediate its effect through a reduction of
the amount of Aβ42 available for the initial seeding and
growth in the size of amyloid plaque core, and maybe
less through the subsequent growth of plaques by the
addition of Aβ peptides of other lengths.
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may have been the result of the significant reduction in
the amyloid plaque load and/or a direct anti-
inflammatory activity of EVP-0015962. In enzyme assays
for COX-1 and COX-2, the IC50 of EVP-0015962 for
COX-1 was > 10 μM (n = 2), and the percent inhibition
for COX-2 at 30 μM was 56% (n = 2), well above the
in vitro IC50 for Aβ42 (67 nM) and the brain expo-
sures of EVP-0015962 after chronic treatment. However,
effects of EVP-0015962 on other inflammatory pathways
have not been excluded. Nevertheless, since the reactive
gliosis in Tg2576 mice on the control diet was localized
around the amyloid plaques and Aβ can activate astro-
cytes and microglia, as well as induce inflammatory
responses [20], it is likely that the EVP-0015962-induced
decrease in Aβ42 and amyloid plaques at least partially
led to the attenuated reactive gliosis. These data suggest
that a therapy which reduces Aβ42 levels will effectively
reduce amyloid plaque formation and the concomitant
reactive gliosis.
Conclusions
We have demonstrated that EVP-0015962 behaves as a
GSM. The compound was orally bioavailable, detected
in brain, well tolerated after daily treatment in Tg2576
mice, and decreased Aβ deposition and reactive gliosis.
EVP-0015962 was also shown to prevent and/or reverse
hippocampal cognitive deficits associated with the de-
crease in amyloid deposition after chronic treatment.
EVP-0015962 is a novel, small molecule GSM with the
potential to be a well-tolerated, disease-modifying thera-
peutic for Alzheimer’s disease.
Methods
EVP-0015962
EVP-0015962 was synthesized and chirally separated, as
described by Shapiro and Chesworth [54]. For in vitro
experiments, EVP-0015962 was dissolved in dimethyl
sulfoxide (DMSO, Sigma-Aldrich, St. Louis, MO) as a 30
mM stock solution for dilution into medium. For food
formulation studies, EVP-0015962 (20 and 60 mg/kg/
day) was milled into standard mouse chow pellets (AIN-
93M, Research Diets, Inc., New Brunswick, NJ). Diet
doses of EVP-0015962 were calculated based on the
desired single daily dose, body weight, and daily food in-
take. The food formulations of 20 and 60 mg/kg/day
were equivalent to 171 and 514 ppm of EVP-0015962 in
the diet, respectively.
COX enzyme assays
COX-1 and COX-2 enzyme assays were performed by
Cerep (Redmond, WA, Catalog # 0726 and 0727).
Briefly, the assays used human recombinant Sf9 cells
and arachidonic acid (4 μM for COX-1 and 2 μM forCOX-2) as the substrate. Production of PGE2 was
detected by enzyme immunoassay.
Animals
Animals were maintained on 12/12 h light/dark cycle with
food available ad libitum. All procedures were performed
with approval from the Institutional Animal Care and Use
Committee and were in accordance with the guidelines in
the Guide for the Care and Use of Laboratory Animals
from the U.S. Department of Health and Human Services.
Cell-based assay for measuring secreted Aβ peptides
Human neuroglioma H4 cells (ATCC, Manassas, VA) were
transfected with a pcDNA3.1 (Invitrogen, Carlsbad, CA)
plasmid expressing human wild type APP751 cDNA; and a
stable cell line was generated using G418 (Invitrogen) selec-
tion [55]. Prior to experimentation, H4-APP751 cells were
maintained in Dulbecco’s modified Eagle’s high glucose
medium with 10% fetal bovine serum, 1% penicillin-
streptomycin, 2 mM L-glutamine, and 0.4 mg/mL G418.
All culture reagents were from Invitrogen.
Cells were plated at 15,000 cells/well in Costar 96-well
plates (Corning, Corning, NY) and placed at 37°C and
5% CO2. Six hours after plating, cells were washed three
times with Pro293™ chemically defined medium (Lonza,
Walkersville, MD) with 1% penicillin-streptomycin and 2
mM L-glutamine, followed by addition of EVP-0015962
(0.003–10 μM, final DMSO concentration of 0.33%).
Plates were incubated overnight (16–18 h) and super-
natant was removed for quantification of Aβ peptides by
sandwich ELISA. Cytotoxicity was evaluated using Cell-
Titer 96W AQueous One Solution Cell Proliferation
Assay (MTS Assay, Promega, Madison, WI) according
to the manufacturer’s protocol.
Rat primary neocortical cultures
Primary cultures were established from the neocortex of
E17 rat embryos obtained from timed pregnant CD rats
(Charles River Laboratories, Wilmington, MA). Following
tissue dissection and trituration, the cultures were
suspended in Neurobasal™ medium (Invitrogen) supple-
mented with 10% horse serum (Sigma-Aldrich) and 520
μM L-glutamine [56,57]. Cells were plated at 50,000 cells/
well in Costar 96-well poly-D-lysine-coated plates. Follow-
ing incubation at 37°C and 5% CO2 for 4–5 h, the plating
medium was exchanged with NeurobasalW medium with
2% B-27W supplement (Invitrogen), 520 μM of L-glutam-
ine, and 1% penicillin-streptomycin. Assays were per-
formed at day eight in vitro (DIV8) after replacement of
one-half of the medium and addition of EVP-0015962
(0.01–30 μM, final DMSO concentration of 0.1%). Cultures
were incubated with compound for 24 h for analysis of Aβ
peptides by sandwich ELISA and cytotoxicity by MTS
assay.
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Aβ peptide levels were quantified by sandwich ELISA.
Plates were coated overnight at 4°C with either human
anti-AβTotal (amino acids [aa] 27–37) or rodent anti-
Aβ1-x (aa 1–8) rabbit polyclonal antibodies. For detec-
tion of Aβ38 and Aβ42, plates were coated with anti-
bodies specific for the carboxyl-terminal neoepitope of
each peptide. Antibodies were from Dr. Pankaj Mehta
(Institute for Basic Research in Developmental Disabil-
ities, Staten Island, NY) [58].
Freshly collected samples of cultured cell supernatant
or synthetic peptides (American Peptide Co., Sunnyvale,
CA or California Peptide Research, Inc., Napa, CA) for
standard curves were diluted with media, and loaded
into anti-Aβ antibody-coated plates and incubated at 4°
C for about 24 h. Aβ peptides were detected with the
4G8 antibody (Aβ, aa 17–24) conjugated to horseradish
peroxidase (Covance, Inc., Princeton, NJ), and SureBlue
3,3’,5,5’-tetramethylbenzidine (TMB) peroxidase sub-
strate (KPL, Inc., Gaithersburg, MA). Following addition
of TMB stop solution (KPL, Inc.), plates were read for
absorbance at 450 nm (SpectraMax M5e Microplate
Reader, Molecular Devices, Inc., Sunnyvale, CA). EVP-
0015962-treated samples were normalized to samples
treated with DMSO alone (no inhibition) and to samples
treated with DAPT (5 μM, Sigma-Aldrich). IC50 and
EC50 values were calculated from values reported as
percent of DMSO controls using nonlinear regression,
based on a sigmoidal dose–response (variable slope)
model. All data were analyzed in Prism 4 (GraphPad
Software, Inc., San Diego, CA).
MALDI-TOF mass spectrometry
Immunoprecipitation of carboxyl-terminally truncated
Aβ peptides from 4 mL of H4 cell media was conducted
using Aβ-specific antibodies coupled to magnetic beads
as described elsewhere [59]. The anti-Aβ antibodies
6E10 and 4G8 (Covance, Inc.) were used. After elution
of the immune-purified Aβ peptides, the detections were
performed on an UltraFlextreme MALDI-TOF/TOF in-
strument (Bruker Daltonics, Bremen, Germany).
AICD production
The effects of increasing concentrations of EVP-
0015962 on cleavage products of APP were tested in
a cell-free system. DAPT was used as a reference
positive control for the assay. For each assay condition,
a 5-μL microsomal fraction, containing 1% CHAPSO
(3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-
1-propanesulfonate) from murine embryonic fibroblasts
(MEF) lacking the Aph-1A, Aph-1B, and Aph-1C genes
[60] (triple knock out) and rescued with Aph-1AL, was
prepared in a reaction mixture of 5 μL substrate (re-
combinant APP β-CTF 3-Flag-tagged) at 0.8 μM,0.0125% phosphatidylethanolamine, 0.1%, phosphatidyl-
choline, 0.05% sphingomyelin, and 8.9 μL PIPES (pi-
perazine-N,N0-bis[−ethanesulfonic acid]) buffer. EVP-
0015962 (0.001–100 μM) or DAPT (10 μM) in 0.5 μL of
DMSO was added to the reaction mixture and incu-
bated at 37°C for 3 h. For detection of AICD, one-half
of the reaction mixture was purified by a methanol-
chloroform extraction in order to remove lipids and
hydrophobic proteins (e.g., APP β-CTF). This purified
fraction was further analyzed by SDS-PAGE and West-
ern blotting. AICD was detected with an ANTI-FLAGW
antibody (Sigma-Aldrich). The other half of the reaction
mixture was used to analyze the levels of Aβ1-40 and
Aβ1-42 by AlphaLisa (Perkin Elmer, Waltham, MA).
APP CTF assays
To evaluate the accumulation of APP α- and β-CTFs,
H4-APP751 cells were treated for 16 h with EVP-
0015962 or the GSI LY-411,575 (Alchem Laboratories
Corp., Alachua, FL) at 0.001–10 μM. Cells were lysed in
situ and the resulting lysate cleared of nuclei by centrifu-
gation, as described elsewhere [61]. Samples were frac-
tionated by SDS-PAGE on a 12% NuPage gel
(Invitrogen), transferred to a nitrocellulose membrane,
and immunoblotted with an anti-APP-CTF antibody
(Sigma-Aldrich). Following incubation with an IRDye
secondary antibody (Li-Cor Biosciences, Lincoln, NE),
detection was performed using an Odyssey scanner
(LiCor Biosciences).
For determination of APP α- and β-CTFs in Tg2576
mouse brain, hemisphere samples were thawed in ice-
cold homogenization buffer (150 mg of tissue/mL, 50
mM Tris and 150 mM NaCl, pH 7.4) with protease in-
hibitor cocktail (Mini Complete™, Roche Applied Sci-
ence, Penzberg, Germany). Homogenized samples were
spun at 435,000 g for 50 min at 4°C. The supernatant
was discarded and the pellet resuspended in the same
volume of homogenization buffer containing 0.5%
TritonW-X 100, 1% deoxycholate, and 3% SDS. The pel-
lets were triturated with a pipette until resuspended and
incubated on a rotator for 1 h at 4°C. The samples were
then centrifuged at 435,000 g for 50 min at 4°C and the
detergent-soluble supernatant was collected. Protein
concentration for membrane (detergent soluble) frac-
tion was determined using the BCA method (Pierce,
Rockford, IL). Thirty micrograms of total protein were
separated on a Tricine 10-20% gel (Invitrogen) and
transferred to a nitrocellulose membrane. Blots were
probed with an anti-APP-CTF antibody (Sigma-Aldrich)
or anti-Aβ antibody (clone 6E10) followed by incuba-
tion with IRDye secondary antibodies (Li-Cor Bios-
ciences). Detection was performed using an Odyssey
scanner (LiCor Biosciences) and blots quantified using
ImageJ software (available at http://rsbweb.nih.gov/ij).
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HEK293 cells (700,000 cells per assay condition) were
transiently transfected with a NotchΔE, myc-tagged con-
struct to produce a truncated Notch1 substrate, which is
constitutively cleaved by γ-secretase (S3 cleavage) [62].
Control transfections were performed with an empty
vector. Twenty-four hours after transfection, the cells
were treated with EVP-0015962 (0.001–30 μM) or
DMSO (control) for 20 h. Lactacystin (10 μM, Sigma-
Aldrich) was used to prevent degradation of NICD. Cell
lysates were analyzed by SDS-PAGE and Western blot-
ting using a c-myc monoclonal antibody (9E10, Santa
Cruz Biotechnology, Santa Cruz, CA) and a cleaved
Notch1 antibody (Cell Signaling Technology, Beverly,
MA). The amounts of NICD and total Notch were quan-
tified and NICD was expressed as a percentage of total
Notch. The DMSO control condition was set at 100%.
Cell viability was determined using the CellTiter-BlueW
Cell Viability Assay (Promega).
EphA4 CTF assay
Rat primary neocortical cultures (DIV14) were treated
with 0.1–10 μM of EVP-0015962 or LY-411,575 for 24 h.
Cells were lysed with RIPA buffer (50 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-
40, and 1 mM EDTA) (Upstate, Temecula, CA) contain-
ing protease inhibitors and samples centrifuged for 8
min at 16,200 g to remove cell debris. Protein concentra-
tion of the lysate was determined by the BCA method,
and 30 μg of total protein were loaded on a 10% Bis-Tris
gel (Invitrogen). EphA4 CTF was visualized using an
anti-EphA4-CTF antibody (Abnova, Walnut, CA) and an
IRDye800CWW secondary antibody (Rockland Immuno-
chemicals, Inc., Gilbertsville, PA). Detection was per-
formed using an Odyssey scanner (LiCor Biosciences)
and blots quantified using ImageJ software (available at
http://rsbweb.nih.gov/ij).
Acute treatment study in Tg2576 mice
EVP-0015962 was prepared in a vehicle of 10% DMSO,
15% SolutolW HS 15 (BASF, Ludwigshafen, Germany),
10% ethyl alcohol, and 65% water. The 10 and 30 mg/kg
doses were a solution and a suspension, respectively.
Male Tg2576 mice (B6;SJL-Tg(APPSWE)2576Kha, model
1349, Taconic, Hudson, NY) were used at 21 weeks of
age [36]. Mice (24–35 g body weight) were administered
10 or 30 mg/kg, p.o. of EVP-0015962 without prior fast-
ing, and euthanized by CO2 asphyxiation 4 h post-dos-
ing. After extraction of the brain, olfactory bulbs and
hindbrain were removed and the cerebral hemispheres
were cut into 4 pieces. Cerebellum was removed for
bioanalysis of EVP-0015962 concentrations. All tissue
samples were weighed, frozen in liquid nitrogen, and
stored at −80°C until analysis.Chronic treatment studies in Tg2576 mice
Male C57BL/6 mice (Charles River Laboratories, 10–12
weeks of age, 24–32 g body weight) were group housed
(3–5 per cage) and used in pilot studies to establish the
concentrations of EVP-0015962 for the food formula-
tions for the chronic treatment studies. Mice were
placed on the food formulations for 3 or 7 days and were
euthanized, as described above, approximately 1 h after
the onset of the light cycle.
Male Tg2576 and WT mice were both derived from
crosses of male Tg2576 mice and female B6SJLF1 mice
(Taconic) and were singly housed upon arrival. At 16–23
weeks of age, mice were placed on the control diet (AIN-
93M), and one week later, were switched to the experi-
mental diets (EVP-0015962 at 20 or 60 mg/kg/day) or
maintained on the control diet. Tg2576 mice were main-
tained on the food formulations containing EVP-0015962
for 11, 28, or 50 weeks, and were sacrificed at 2–4 h after
the onset of the light cycle. Some animals were euthanized
as described above. For histological studies, a subset of
mice were euthanized by CO2 asphyxiation and transcar-
dially perfused with cold 0.9% NaCl. The right hemi-
spheres were immersion fixed in fresh 4%
paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 for 1
h, transferred to a 15% sucrose cryoprotectant for 24 h at
room temperature, and on the next day, frozen in isopen-
tane chilled by dry ice for 1 min. The left cerebral hemi-
sphere was cut into 2 pieces, weighed, and frozen.
Measurement of EVP-0015962 in brain
Cerebellums were homogenized in a Mini-BeadBeater
(Biospec Products, Inc., Bartlesville, OK). Brain samples
and calibration standards in brain homogenate were
prepared for liquid chromatography-tandem mass spec-
troscopy (LC-MS/MS) by precipitating proteins with
acetonitrile and vacuum filtration in the presence of an
internal standard (EVP-0015962-D6). EVP-0015962 was
resolved by HPLC (Shimadzu, Kyoto, Japan) using a
reverse-phase XterraW C18 column (100 × 2.1 mm i.d.)
(Waters Corp., Milford, MA). Following separation,
the column effluent was introduced into a hybrid triple
quadrupole/linear ion trap mass spectrometer (API 3200
Q-Trap, Applied Biosystems, Foster City, CA), optimized
for detection of EVP-0015962 and using multiple reaction
monitoring with mass transition of 479.300>296.700. Con-
centration of EVP-0015962 was measured as nanograms
per gram of brain and expressed as micromolar.
Sequential Aβ extraction from Tg2576 mouse brain
In order to examine both soluble and insoluble pools of
Aβ, sequential extraction of Tg2576 mouse brain samples
was performed to produce 4 pools of Aβ, essentially as
described elsewhere [37]. Briefly, brains were homogenized
in 25 mM TBS, pH 7.4 with protease inhibitors (Mini
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supernatants after high speed ultracentrifugation. The
above procedure was then repeated with the pellets from
the previous extraction step, using 1% TritonW-X 100 in
TBS with protease inhibitors, 2% SDS with protease inhibi-
tors, and 68.75% formic acid. The extracted Aβ from each
step was subjected to ELISA for human Aβ42, Aβ38, and
AβTotal, as described above.
Detection of aggregated Aβ in Tg2576 mouse brain
The A4 assay (Amorfix Life Sciences, Toronto, Canada)
was employed to quantify levels of aggregated Aβ in
Tg2576 mouse brains. Brain samples were homogenized
in 10 volumes of 2% NP-40 in phosphate buffered saline
(PBS, pH 7.4) containing 1 mM phenylmethanesulfonyl-
fluoride (PMSF) and protease inhibitors (Mini
Complete™). The homogenates were further diluted in
PBS with 0.05% TweenW 20 and 1% bovine serum albu-
min to a final concentration that would provide a signal
within the linear range of the immunoassay. A sample
enrichment protocol, proprietary to Amorfix Life
Sciences, was used to specifically isolate oligomeric and
aggregated Aβ rather than monomeric Aβ. Following en-
richment, samples were eluted and disaggregated to
allow detection of now monomeric Aβ [63]. Aβ was
detected by immunoassay following incubation at 37°C
with europium-fluorescent beads coupled to the mouse
monoclonal 4G10 antibody (N-terminal Aβ, aa 1–
17) and magnetic beads coupled to the antibodies 1F8
(C-terminal Aβ, aa 3–40) and 2H12 (C-terminal Aβ, aa
3–42). 4G10, 1F8, 2H12 were produced by Amorfix Life
Sciences. Following incubations the samples were
placed on a magnet to isolate the immune complex. The
intensity of the europium fluorescent signal was measured
using time resolved fluorescence on each sample in tripli-
cate and was taken as being directly proportional to the
concentration of aggregated Aβ in the sample. The limit
of detection using this assay was 50 fg per well. The fluor-
escent signal for each mouse relative to the background
noise for the assay was then expressed as percent of the
control diet group.
Histology
The right hemispheres were sectioned at 20 μm in the sa-
gittal plane. From 12 levels, 7 sections were retained and
processed. Aβ plaque load was quantified in sections
doubly stained by immunohistochemistry with 6E10 anti-
body (N-terminal human Aβ, aa 1–16) and by ThioflavinS.
Astrocytes were immunostained using a primary rabbit
polyclonal antibody against GFAP (Dako, Glostrup, Den-
mark) and a fluorescently labelled secondary Cy2 antibody
(Jackson ImmunoResearch Laboratories, West Grove,
PA). Activated microglia were immunostained using a rat
anti-murine CD11b primary antibody (AbD Serotec,Kidlington, UK) and a fluorescently labelled secondary
Cy3 antibody (Jackson ImmunoResearch Laboratories).
Astrocytes and microglia were labelled in a double incuba-
tion and sections were counterstained with DAPI to
visualize cell nuclei.
Hippocampus and neocortex were measured separately,
and the percent area of immunoreactivity or ThioflavinS
staining per brain region was evaluated using automated
image analysis software (Image Pro Plus, v. 6.2, Media
Cybernetics, Bethesda, MD). Numbers and sizes of Aβ
deposits were also counted automatically. Measurements
from 5 sections per mouse were averaged and the individ-
ual mouse average was used to calculate the group means.
Contextual fear conditioning assay
A 2-day CFC paradigm was used, and the effects of
acute and chronic dosing of EVP-0015962 were assessed.
For the acute study, EVP-0015962 was prepared as a
suspension in a vehicle of 4.5% DMSO, 15% SolutolW HS
15, 10% ethyl alcohol, and 70.5% water. On day 1, acutely
dosed mice were administered 30 mg/kg, p.o. of EVP-
0015962, 3 h prior to training. Animals in the food formu-
lation groups were maintained on the compound formu-
lated diets. The training session on day 1 consisted of the
following sequence: 3 min acclimation to the test chamber
(Kinder Scientific, Poway, CA), 2 s 1.5 mA foot shock, 2
min wait period, another 2 s 1.5 mA foot shock, followed
by a final 1 min wait period. On day 2, testing consisted of
returning the animals to the chamber for 5 min and the
total time spent freezing was measured by an automated
software system (Kinder Scientific). Freezing was defined as
the absence of movement (i.e., zero beam breaks) and was
measured every second for the 5-min trial duration (max-
imum freezing score of 300). Percentage of time spent
freezing for each mouse was calculated using the formula:
(number of seconds with zero beam breaks/300) X 100.
Statistics
In vivo data were expressed and graphed as mean ± SEM.
Group differences for Aβ peptide levels, APP processing
fragments, histological measures, and behavioral measures
were assessed by one-way analyses of variance (ANOVA)
followed by Newman-Keuls post-hoc testing or by Stu-
dent’s t-test. Differences in aggregated Aβ were assessed
by non-parametric Kruskal-Wallis ANOVA followed by
Dunn’s test since the groups did not have equal variances.
The level of significance was set at p < 0.05 in all tests.
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